Bridgebio Pharma Inc
Open
SectorGezondheidszorg
67 0.22
Overzicht
Wijziging aandelenprijs
24u
Min
65.64
Max
67.79
Inkomsten | 24M -167M |
|---|---|
Verkoop | 40M 195M |
EPS | -0.84 |
Winstmarge | -85.626 |
Werknemers | 834 |
EBITDA | 75M -105M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +59.75% upside |
Volgende Winsten | 4 aug 2026 |
|---|
Marktkapitalisatie | -132M 13B |
|---|---|
Vorige openingsprijs | 66.78 |
Vorige sluitingsprijs | 67 |
Nieuwssentiment
By Acuity
34%
66%
94 / 342 Rangschikking in Healthcare
Bridgebio Pharma Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Bridgebio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.